---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-081592"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:42:14.699562+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma prices $20M public offering; $13.1M cash; runway into Q2 2026

## Summary
- Pricing of 13.53M common shares + warrants at $0.79/unit; $20M gross proceeds.
- Net proceeds estimated at $18M; closing expected April 16, 2025.
- Preliminary cash and cash equivalents of $13.1M as of March 31, 2025 (unaudited).
- Including $12M upfront from Boehringer Ingelheim deal, cash runway extended into Q2 2026.
- Offering includes pre-funded warrants for 11.47M shares at $0.001 exercise price.

## SEC filing metadata
- accession: 0001193125-25-081592
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312525081592/0001193125-25-081592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312525081592/d923668d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-081592
- JSON: https://secwatch.observer/filing/0001193125-25-081592.json
- Plain text: https://secwatch.observer/filing/0001193125-25-081592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.